Cansino issued an announcement of abnormal stock trading fluctuations. The company is concerned about the recent development of mRNA technology in the market and the release or planned disclosure of clinical phase data for overseas mRNA cancer vaccines. The mRNA platform is one of the technology platforms in the company's layout. The company is developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In the field of treatment, the company is promoting research and development of mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of in-viVocar related therapies, which are currently in the early stages.

Zhitongcaijing · 1d ago
Cansino issued an announcement of abnormal stock trading fluctuations. The company is concerned about the recent development of mRNA technology in the market and the release or planned disclosure of clinical phase data for overseas mRNA cancer vaccines. The mRNA platform is one of the technology platforms in the company's layout. The company is developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In the field of treatment, the company is promoting research and development of mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of in viVocar related therapies, which are currently in the early stages.